Psoriasis, Inflammation, and a Study That Landed in January 2026
Psoriasis is a chronic inflammatory skin condition, and a study published in January 2026 looked specifically at MAH's effect on it — measuring both disease severity and inflammatory blood markers before and after treatment. It's a strong, specific piece of evidence, and worth walking through properly rather than just citing the headline result.
What the study actually did
Researchers at Afyonkarahisar Health Sciences University in Turkey studied 26 psoriasis patients undergoing major autohemotherapy (MAH ozone), comparing their disease severity and inflammatory blood markers before and after treatment, against 19 healthy control subjects for baseline reference. Disease severity was measured using PASI — the Psoriasis Area and Severity Index, the standard clinical scale dermatologists use to track how psoriasis responds to any treatment.
After MAH, PASI scores dropped significantly.
Several inflammatory blood markers — including CRP (a general marker of inflammation) and Siglec-14 (linked to immune cell signalling) — decreased too, both in patients with mild psoriasis and in those with moderate-to-severe disease.
What kind of evidence this is — and isn't
This is a real, peer-reviewed, MAH-specific human study — a strong starting point. It's worth being precise about its shape, though: it measured patients before and after treatment, rather than comparing MAH against a placebo or sham treatment. That means it shows a genuine, measured change — it doesn't yet rule out other explanations for that change the way a placebo-controlled trial would. It's also a single study, with 26 patients — encouraging, but not yet replicated elsewhere.
Put simply: this is a real result worth taking seriously, not proof in the fullest clinical sense. That distinction matters, and we'd rather you have it than not.
Why this fits with what we already know about ozone
This connects directly to the mechanism covered in our immune modulation piece — psoriasis is, at its core, an inflammatory condition driven by immune signalling that's become dysregulated. The same cytokine-balancing effect that applies to joint and muscle inflammation appears to extend to skin-level inflammatory markers too, which is consistent with what this study found.
What this looks like in practice
If you're managing psoriasis, this is genuinely worth raising at consultation. It's not a replacement for your dermatologist or your current treatment plan — we'll always coordinate around your existing care rather than in place of it.
Frequently Asked Questions
-
No single study establishes that. What it shows is a measurable, biomarker-level change worth discussing seriously — not a guaranteed outcome.
-
No — we'll never suggest stepping away from your dermatologist's care. This is something to explore alongside your existing treatment, not instead of it.
Have a question this article didn't answer? Get in touch — I read every message myself.
Look after your little self,
Marianne x
